Select Publications
Book Chapters
2020, 'Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: How effective are they?', in Clinical Dilemmas in Viral Liver Disease, Second Edition, pp. 106 - 111, http://dx.doi.org/10.1002/9781119533481.ch18
,2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
,2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press
,2010, 'Interferon Alfa', in Kucers' The Use of Antibiotics Sixth Edition, CRC Press, pp. 2959 - 2975, http://dx.doi.org/10.1201/b13787-291
,2009, 'Acute hepatitis C infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 230 - 253
,Journal articles
2024, 'Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study', The Lancet Regional Health - Western Pacific, 53, http://dx.doi.org/10.1016/j.lanwpc.2024.101240
,2024, 'Testing, diagnosis, and treatment following the implementation of a program to provide dried blood spot testing for HIV and hepatitis C infections: the NSW DBS Pilot', BMC Infectious Diseases, 24, http://dx.doi.org/10.1186/s12879-024-08989-8
,2024, 'A Pilot Randomised Controlled Trial Involving Financial Incentives to Facilitate Hepatitis C Treatment Uptake Among People Who Inject Drugs: ETHOS Engage Study', Viruses, 16, http://dx.doi.org/10.3390/v16111763
,2024, 'Hepatitis C treatment outcome among people in prison: The SToP-C study', Liver International, 44, pp. 2996 - 3007, http://dx.doi.org/10.1111/liv.16074
,2024, 'Point-of-Care Testing for Hepatitis C Infection: A Critical Building Block for the Foundation to Achieve Elimination', Clinical Infectious Diseases, 79, pp. 974 - 977, http://dx.doi.org/10.1093/cid/ciae156
,2024, 'Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia', The Lancet Regional Health - Western Pacific, 51, http://dx.doi.org/10.1016/j.lanwpc.2024.101185
,2024, 'Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis', The Lancet Public Health, 9, pp. e684 - e699, http://dx.doi.org/10.1016/S2468-2667(24)00160-9
,2024, 'Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons', International Journal of Drug Policy, 130, http://dx.doi.org/10.1016/j.drugpo.2024.104516
,2024, 'Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study', International Journal of Drug Policy, 129, http://dx.doi.org/10.1016/j.drugpo.2024.104477
,2024, 'Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study', Drug and Alcohol Review, 43, pp. 1080 - 1092, http://dx.doi.org/10.1111/dar.13688
,2024, 'The cost-effectiveness of integrating simplified HCV testing into HIV pre-exposure prophylaxis (PrEP) and treatment services among men who have sex with men in Taiwan', The Lancet Regional Health - Western Pacific, 48, http://dx.doi.org/10.1016/j.lanwpc.2024.101119
,2024, 'Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104468
,2024, 'Patterns of drug use among people who inject drugs: A global systematic review and meta-analysis', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104455
,2024, 'Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis', eClinicalMedicine, 72, http://dx.doi.org/10.1016/j.eclinm.2024.102596
,2024, 'Where to next for the international journal of drug policy: A continued focus on multidisciplinary research, community involvement, and impact', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104447
,2024, '96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104390
,2024, 'Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104394
,2024, 'Health utility among people who regularly use opioids in Australia', Drug and Alcohol Review, 43, pp. 997 - 1012, http://dx.doi.org/10.1111/dar.13823
,2024, 'Impact of simplified HCV diagnostic strategies on the HCV epidemic among men who have sex with men in the era of HIV oral pre-exposure prophylaxis in Taiwan: a modelling study', Journal of the International AIDS Society, 27, http://dx.doi.org/10.1002/jia2.26251
,2024, 'Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study', Drug and Alcohol Review, 43, pp. 1019 - 1028, http://dx.doi.org/10.1111/dar.13828
,2024, 'Vaccination coverage among people who inject drugs: A systematic review', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104382
,2024, 'Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions', The Lancet Gastroenterology and Hepatology, 9, pp. 366 - 382, http://dx.doi.org/10.1016/S2468-1253(23)00335-7
,2024, 'Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update', The Lancet Gastroenterology and Hepatology, 9, pp. 346 - 365, http://dx.doi.org/10.1016/S2468-1253(23)00321-7
,2024, 'Reply to: “ ‘One-stop-shop’ point-of-care hepatitis C RNA testing intervention in the prison – some issues”', Journal of Hepatology, 80, pp. e107 - e108, http://dx.doi.org/10.1016/j.jhep.2023.10.020
,2024, 'Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study', Value in Health, 27, pp. 216 - 225, http://dx.doi.org/10.1016/j.jval.2023.10.013
,2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofad637
,2024, 'Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2024.104401
,2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895
,2024, 'Provider costs of treating opioid dependence with extended-release buprenorphine in Australia', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.13956
,2024, 'The time of cure: hepatitis C treatment and the matter of reinfection among people who inject drugs', Health Sociology Review, 33, pp. 104 - 118, http://dx.doi.org/10.1080/14461242.2024.2315031
,2024, 'We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?', Expert Review of Molecular Diagnostics, 24, pp. 177 - 191, http://dx.doi.org/10.1080/14737159.2023.2292645
,2023, 'Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study', Implementation Science, 18, http://dx.doi.org/10.1186/s13012-023-01281-4
,2023, 'Effect of incarceration and opioid agonist treatment transitions on risk of hospitalisation with injection drug use-associated bacterial infections: A self-controlled case series in New South Wales, Australia', International Journal of Drug Policy, 122, http://dx.doi.org/10.1016/j.drugpo.2023.104218
,2023, 'Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e1885 - e1898, http://dx.doi.org/10.1016/S2214-109X(23)00461-8
,2023, 'Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study', Drug and Alcohol Review, 42, pp. 1617 - 1632, http://dx.doi.org/10.1111/dar.13723
,2023, 'Health-related quality of life among people who inject drugs in Australia', Quality of Life Research, 32, pp. 3195 - 3207, http://dx.doi.org/10.1007/s11136-023-03465-3
,2023, 'Hepatitis C Treatment Uptake Following Dried Blood Spot Testing for Hepatitis C RNA in New South Wales, Australia: The NSW DBS Pilot Study', Open Forum Infectious Diseases, 10, http://dx.doi.org/10.1093/ofid/ofad517
,2023, 'Joint statement in support of hepatitis C human challenge studies', The Lancet Gastroenterology and Hepatology, 8, pp. 967 - 969, http://dx.doi.org/10.1016/S2468-1253(23)00314-X
,2023, 'Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study', JHEP Reports, 5, http://dx.doi.org/10.1016/j.jhepr.2023.100867
,2023, 'Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study', The Lancet Gastroenterology and Hepatology, 8, pp. 879 - 907, http://dx.doi.org/10.1016/S2468-1253(23)00197-8
,2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890, http://dx.doi.org/10.1097/QAD.0000000000003651
,2023, 'A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study', Journal of Hepatology, 79, pp. 635 - 644, http://dx.doi.org/10.1016/j.jhep.2023.04.019
,2023, 'Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis', Addiction, 118, pp. 1624 - 1648, http://dx.doi.org/10.1111/add.16200
,2023, 'Typology of laws restricting access to methadone treatment in the United States: A latent class analysis', International Journal of Drug Policy, 119, http://dx.doi.org/10.1016/j.drugpo.2023.104141
,2023, 'Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis', The Lancet Microbe, 4, pp. e622 - e631, http://dx.doi.org/10.1016/S2666-5247(23)00108-8
,